Redcare Pharmacy raises 2026 guidance, shares in focus after strong Q1

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 11:39.

Redcare Pharmacy (NL0012044747) lifts its full-year 2026 guidance after what management calls an accelerated start to the year. According to its June 2026 investor communication, the Xetra-listed online pharmacy reports faster growth, improved profitability and higher targets for sales and adjusted EBITDA. June 2026 company presentation

What Redcare just updated

Redcare Pharmacy, formerly Shop Apotheke Europe, highlights in its June 2026 presentation that it "accelerates growth, improves profitability and raises full-year 2026 guidance" for the group. Investor presentation overview The company operates leading digital pharmacy platforms in Germany, Austria, France, Belgium, Italy and the Netherlands, and positions itself as a pan-European digital health player.

Management now targets 2026 gross merchandise volume and revenue growth in the mid-teens percentage range, with a higher adjusted EBITDA margin corridor than previously indicated, according to the same document. June 2026 company presentation The upgrade follows strong operational momentum in 2025 and early 2026, including sustained order growth and a rising share of repeat customers.

How analysts view the shares

On the analyst side, several houses have recently reiterated positive views on Redcare Pharmacy after Germany’s e-prescription rollout and the updated guidance. MarketScreener data show a majority of covering analysts rating the stock as Buy, with an average price target above the current Xetra quotation. MarketScreener consensus overview The company is often compared with peers such as Zur Rose’s DocMorris in Switzerland in the European online pharmacy segment.

In recent commentary, Deutsche Bank and other brokers highlight Redcare’s leverage to structural growth in online health-care spending and to the German e-prescription ramp-up, which simplifies digital dispensing of prescription drugs. Handelsblatt analysis on online pharmacies For investors, the combination of raised guidance, higher scale and improving margins has become a central part of the equity story.

How Redcare makes its money

Redcare Pharmacy generates the bulk of its revenue through its online pharmacy and digital health platforms, primarily under the shop-apotheke.com brand in Germany and local brands in other EU markets. Company brand overview The product range spans prescription drugs, over-the-counter medicines, beauty and personal care items, and health-related consumer goods.

Where the stock trades today

The Redcare Pharmacy shares (NL0012044747) most recently traded on Xetra at 120.40 euros as of 2026-06-26, 11:30.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Figures and facts are based on sources considered reliable but cannot be guaranteed. Investors should conduct their own research or consult a financial advisor before making investment decisions.